OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.
Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.
To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.
LEARNING OBJECTIVES
Please see individual web programs for CME program-specific information.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Please see individual web programs for CME program-specific information.
HOW TO USE THIS CME ACTIVITY
Please see individual web programs for CME program-specific information.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Please see individual web programs for CME program-specific information.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Seattle Genetics and Spectrum Pharmaceuticals Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: January/February/March/May 2014
Expiration date: January/February/March/May 2015
Overview This 7-part web program is part of an email series designed for dedicated but frenzied oncology professionals attempting to keep up with an exploding clinical research database. Subscribers to this program receive weekly emails that include links to slides from important data sets presented at ASH 2013 along with brief comments from clinical investigators about the significance of these results. Current Issue 
Read Dr Love’s original email (May 14, 2014)
Novel Approaches to the Treatment of B-Cell Lymphoma and Acute Leukemias
Program Description: A summary of recent data assessing the efficacy and safety of chimeric antigen receptor-engineered T cells for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and B-cell lymphoma and the efficacy of gemtuzumab ozogamicin and novel therapeutic agents in acute myeloid leukemia.
Full Abstracts:
T Cells Engineered with CAR Targeting CD19 in Patients with Relapsed/Refractory ALL
Grupp SA et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Proc ASH 2013; Abstract 67.
CAR-Modified T Cells Directed Against CD19 in Relapsed/Refractory CLL
Porter DL et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. Proc ASH 2013; Abstract 873.
Porter DL et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Proc ASH 2013; Abstract 4162.
Phase I Trial of CD19-Targeted CAR-Modified T Cells as Consolidation for Previously Untreated CLL
Park JH et al. Phase I trial of autologous CD19-targeted CAR-modified T cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. Proc ASH 2013; Abstract 874.
Reinduction of Complete Remissions Using 19-28z CAR T-Cell Therapy in Relapsed B-Cell ALL
Davila M et al. Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy. Proc ASH 2013; Abstract 69.
Anti-CD19 CAR T-Cell Therapy in Children with Relapsed/Refractory ALL
Lee DL et al. Anti-CD19 chimeric antigen receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (HSCT). Proc ASH 2013; Abstract 68. Treatment of Chemotherapy-Refractory DLBCL with Anti-CD19 CAR T Cells
Kochenderfer JN et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor. Proc ASH 2013; Abstract 168.
ASH 2013 Highlights with Novel Therapeutic Agents in AML
Cortes JE et al. Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML). Proc ASH 2013; Abstract 494.
Kantarjian HM et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Proc ASH 2013; Abstract 497.
Marucci G et al. Adding the KIT inhibitor dasatinib (DAS) to standard induction and consolidation therapy for newly diagnosed patients (pts) with core binding factor (CBF) acute myeloid leukemia (AML): Initial results of the CALGB 10801 (Alliance) study. Proc ASH 2013; Abstract 357.
Visani G et al. Low-dose lenalidomide plus low dose cytarabine induce complete remission that can be predicted by genetic profiling in very elderly acute myeloid leukemia patients. Proc ASH 2013; Abstract 496.
ASH 2013 Highlights with Gemtuzumab Ozogamicin in AML
Gamis A et al. Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk — Results from the randomized phase III Children’s Oncology Group (COG) trial, AAML0531. Proc ASH 2013; Abstract 355.
Burnett AK et al. Reasons for survival improvement in core binding factor AML: A 25 year analysis of the UK MRC/NCRI AML trials. Proc ASH 2013; Abstract 358.
Hills RK et al. The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: Results of an individual patient meta-analysis of the five randomised trials. Proc ASH 2013; Abstract 356.
Issue 6 — March 26, 2014 Issue 5 — March 13, 2014 
Read Dr Love’s original email (March 13, 2014)
Novel Agents and Regimens for Multiple Myeloma and Waldenström’s Macroglobulinemia
Program Description: A summary of recent data on the safety and efficacy of novel therapeutic agents and regimens for newly diagnosed and relapsed/refractory multiple myeloma and Waldenström’s macroglobulinemia.
Full Abstracts:
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM
Korde N et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Proc ASH 2013; Abstract 538.
Carfilzomib/Cyclophosphamide/Dexamethasone for Newly Diagnosed MM
Bringhen S et al. A Phase II study with carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma. Proc ASH 2013; Abstract 685.
Carfilzomib/Pomalidomide and Dexamethasone for Relapsed/Refractory MM
Shah JJ et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Proc ASH 2013; Abstract 690.
Pomalidomide and Low-Dose Dexamethasone for Relapsed/Refractory MM
Dimopoulos MA et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a Phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Proc ASH 2013; Abstract 408.
Ixazomib in Combination with Lenalidomide/Dexamethasone for Newly Diagnosed MM
Richardson PG et al. Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (Pts) with newly diagnosed multiple myeloma (MM): Final Phase 1 results and Phase 2 data. Proc ASH 2013; Abstract 535.
SAR650984, a CD38 Monoclonal Antibody, for Patients with Selected CD38+ Hematologic Cancers
Martin TG et al. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies — Data from a dose-escalation Phase I study. Proc ASH 2013; Abstract 284.
Filanesib (ARRY-520), a Selective Inhibitor of Kinesin Spindle Protein, for Patients with Relapsed/Refractory MM
Lonial S et al. Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: Results from a Phase 2 study. Proc ASH 2013; Abstract 285.
Novel AKT Inhibitor Afuresertib and Bortezomib/Dexamethasone for Relapsed/Refractory MM
Voorhees PM et al. Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with relapsed/refractory multiple myeloma. Proc ASH 2013; Abstract 283.
Carfilzomib/Rituximab/Dexamethasone for Relapsed/Refractory Waldenström’s Macroglobulinemia
Treon SP et al. Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom’s macroglobulinemia. Proc ASH 2013; Abstract 757.
BTK Inhibitor Ibrutinib for Relapsed/Refractory Waldenström’s Macroglobulinemia
Treon SP et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Proc ASH 2013; Abstract 251.
Issue 4 — March 6, 2014 
Read Dr Love’s original email (March 6, 2014)
Management of Chronic Lymphocytic Leukemia
Program Description: A summary of recent data on the safety and efficacy of rituximab-based therapies, Btk, BCL-2 and selective PI3 kinase inhibitors and third-generation anti-CD20 antibodies in chronic lymphocytic leukemia.
Full Abstracts:
Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions
Goede V et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final Stage 2 results of the CLL11 trial. Proc ASH 2013; Abstract 6.
Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;[Epub ahead of print]. Abstract
Obinutuzumab with Fludarabine/Cyclophosphamide or Bendamustine as First-Line Therapy for CLL
Brown JR et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): Results from the Phase 1b Galton trial (GAO4779g). Proc ASH 2013; Abstract 523.
Interim Analysis of the Phase III CLL10 Trial: FCR versus Bendamustine/Rituximab for Fit Patients with Previously Untreated CLL
Eichhorst B et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Proc ASH 2013; Abstract 526.
Single-Agent Ibrutinib for Patients with CLL with and without Deletion 17p
Farooqui M et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p. Proc ASH 2013; Abstract 673.
Updated Results of a Phase II Trial of Ibrutinib and Rituximab for High-Risk CLL
Burger JA et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): New, updated results of a Phase II trial in 40 patients. Proc ASH 2013; Abstract 675.
Activity and Tolerability of Ibrutinib with Bendamustine/Rituximab for Relapsed/Refractory CLL/SLL
Brown JR et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: Final results of a Phase 1b study. Proc ASH 2013; Abstract 525.
Phase III Study of Idelalisib and Rituximab for Previously Treated CLL
Furman RR et al. A Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Proc ASH 2013; Abstract LBA-6.
Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;[Epub ahead of print]. Abstract
BCL-2 Inhibitor ABT-199 Monotherapy for High-Risk Relapsed/Refractory CLL or SLL
Seymour JF et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Proc ASH 2013; Abstract 872.
Issue 3 — February 21, 2014 Issue 2 — February 7, 2014 Issue 1 — January 30, 2014
|
